If we hold our hands up in front of our faces,
we see mirror images.
Yet instantly recognize they’re not interchangeable.
That simple idea sits at the heart of the 2026 Nobel Prize in Chemistry.
Henri B. Kagan and Kenso Soai won for discoveries about mirror-image molecules.
Differences in molecular shape can change how a medicine works in our bodies.
Discoveries like these open possibilities across healthcare.
AI, synthetic biology, and automation help us turn those possibilities into treatments people can access:
→ Development: Identify and prioritize promising medicines for testing.
→ Clinical trials: Find eligible patients and open sites sooner.
→ Production: Automate quality checks to support consistent manufacturing.
→ Access: Bring trials closer to where patients receive care.
→ Doctors: Connect molecular results with patient histories to inform treatment decisions.
Tempus connects molecular data with patient records to identify potential trial matches.
At one cancer center, Tempus-supported trials were ready to enroll patients in 14 days instead of 55, a roughly 75% reduction. (ASCO, May 2026)
For families facing cancer, Parkinson’s, or Alzheimer’s, time matters.
We all want more time with the people we love.
That’s the business of human advancement.
Turning scientific possibilities into care people can access.
Giving us more reason for hope.
Execution Beats Theory. Every Time.
👋 Hi, I’m Tim. I help engineering-led startups and mid-market scaleups build adaptive GTM systems, unify revenue, and scale with Agentic AI.
@Entry Point 1 #gtm #agenticai #healthtech
vc: NHS
Key GTM questions
Straight answers
Related GTM concepts
